Transcription factor AP-2α represses both the mucin MUC4 expression and pancreatic cancer cell proliferation

Carcinogenesis

Volumn 28, Issue 11, 2007, Pages 2305-2312

  Fauquette, Valérie ^a,b   Aubert, Sébastien ^a,b,d   Groux degroote, Sophie ^c   Hemon, Brigitte ^a,b   Porchet, Nicole ^a,b,d   Van seuningen, Isabelle ^a,b   Pigny, Pascal ^a,b,d  

^a INSERM   (France)

^b JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^c UNIVERSITÉ DES SCIENCES ET TECHNOLOGIES DE LILLE   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOMUCIN; CIS ACTING ELEMENT; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MESSENGER RNA; MUCIN; MUCIN 4; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR AP 2ALPHA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER INVASION; CELL INVASION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENDOCRINE CELL; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MITOSIS INHIBITION; PANCREAS ADENOCARCINOMA; PANCREAS DUCT; PRECANCER; PRIORITY JOURNAL; PROMOTER REGION; TUMOR SUPPRESSOR GENE; UPREGULATION;

EID: 36249016867     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm158     Document Type: Article

References (37)

1. Takaori,K. et al. (2004) Pancreatic intraepithelial neoplasia. Pancreas, 28, 257-262.
2. Libermann,T.A. et al. (2006) Targeting transcription factors for cancer gene therapy. Curr. Gene Ther., 6, 17-33.
3. Eckert,D. et al. (2005) The AP-2 family of transcription factors. Genome Biol., 6, 246.
4. Eloranda,J.J. et al. (2002) Transcription factor AP-2 interacts with the SUMO-conjugating enzyme UBC9 and is sumolated in vivo. J. Biol. Chem., 277, 30798-30804.
5. Hilger-Eversheim,K. et al. (2000) Regulatory roles of AP-2 transcription factors in vertebrate development, apoptosis and cell-cycle control. Gene, 260, 1-12.
6. Gershenwald,J.E. et al. (2001) Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo. Oncogene, 20, 3363-3375.
7. Jean,D. et al. (1998) Loss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumour growth and metastasis of human melanoma cells. J. Biol. Chem., 273, 16501-16508.
8. Sumigama,S. et al. (2004) Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cells by overexpression of AP-2alpha. Oncogene, 23, 5496-5504.
9. Vernimmen,D. et al. (2003) Identification of HTF (HER2 transcription factor) as an AP-2 (activator protein-2) transcription factor and contribution of the HTF binding site to ERBB2 gene overexpression. Biochem. J., 370, 323-329.
10. Moniaux,N. et al. (1999) Complete sequence of the human mucin MUC4: A putative cell membrane-associated mucin. Biochem. J., 338, 325-333.
11. Carraway,K.L.3rd et al. (1999) An intramembrane modulator of the ErbB2 receptor tyrosine kinase that potentiates neuregulin signaling. J. Biol. Chem., 274, 5263-5266.
12. Balagué,C. et al. (1995) In situ hybridization shows distinct patterns of mucin gene expression in normal, benign, and malignant pancreatic tissues. Gastroenterology, 109, 953-964.
13. Andrianafahanana,M. et al. (2001) Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: A potential role of MUC4 as a tumour marker of diagnostic significance. Clin. Cancer Res., 7, 4033-4040.
14. Swartz,M.J. et al. (2002) MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am. J. Clin. Pathol., 117, 791-796.
15. Saitou,M. et al. (2005) MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas. J. Clin. Pathol., 58, 845-852.
16. Perrais,M. et al. (2001) Characterisation of human mucin gene MUC4 promoter: Importance of growth factors and proinflammatory cytokines for its regulation in pancreatic cancer cells. J. Biol. Chem., 276 30923-30933.
17. Mariette,C. et al. (2004) Transcriptional regulation of human mucin MUC4 by bile acids in oesophagus cancer cells is promoter dependent and involves activation of phosphatidylinositol 3-kinase signalling pathway. Biochem. J., 377, 1-8.
18. Van der Sluis,M. et al. (2004) The murine Muc2 mucin gene is transcriptionally regulated by the zinc-finger GATA-4 transcription factor in intestinal cells. Biochem. Biophys. Res. Commun., 325 952-960.
19. Fauquette,V. et al. (2005) The antagonist regulation of the human MUC4 and ErbB-2 genes by the Ets protein PEA3 in pancreatic cancer cells: Implications for the proliferation/differentiation balance in the cells. Biochem. J., 386, 35-45.
20. Piessen,G. et al. (2007) Regulation of the human mucin MUC4 by taurodeoxycholic and taurochenodeoxycholic bile acids in oesophageal cancer cells is mediated by hepatocyte nuclear factor 1alpha. Biochem. J., 402, 81-91.
21. Wajapeyee,N. et al. (2005) Activator protein 2alpha status determines the chemosensitivity of cancer cells: Implications in cancer chemotherapy. Cancer Res., 65, 8628-8634.
22. Van Seuningen,I. et al. (1995) The K protein domain that recruits the IL-1 responsive K protein kinase lies adjacent to a cluster of c-Src and Vav SH3-binding sites. Implications that K protein acts as a docking platform. J. Biol. Chem., 270, 26976-26985.
23. Singh,A.P. et al. (2004) Inhibition of MUC4 expression suppresses pancreatic tumour cell growth and metastasis. Cancer Res., 64 622-630.
24. Tellez,C. et al. (2003) Role and regulation of the thrombin receptor (PAR-1) in human melanoma. Oncogene, 22, 3130-3137.
25. WAF1/CIP1 expression. Nat. Genet, 15, 78-82.
26. Schwartz,B. et al. (2007) Loss of AP-2α results in deregulation of E-cadherin and MMP-9 and an increase in tumorigenicity of colon cancer cells in vivo. Oncogene, 26, 4049-4058.
27. Motonaga,K. et al. (2002) Age related expression of werner's syndrome protein in selected tissues and coexpression of transcription factors. J. Clin. Pathol., 55, 195-199.
28. Ruiz,M. et al. (2001) AP-2α transcription factor expression is associated with luminal differentiation and is lost in prostate cancer. Clin. Cancer Res., 7, 4086-4095.
29. Adriance,M.C. et al. (2004) Downregulation of Muc1 in MMTV-c-Neu tumours. Oncogene, 23, 697-705.
30. Mc Pherson,L.A. et al. (2002) Tumour suppressor activity of AP-2α mediated through a direct interaction with p53. J. Biol. Chem., 277, 45028-45033.
31. Loukopoulos,P. et al. (2004) Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumours and displaying varying metastatic activity. Pancreas, 29, 193-203.
32. Eisold,S. et al. (2004) The effect of adenovirus expressing wild type p53 on 5 fluorouracil chemosensitivity is related to p53 status in pancreatic cancer cell lines. World J. Gastroenterol., 10, 3583-3589.
33. Lu,C.D. et al. (1999) Loss of p27Kip1 expression independently predicts poor prognosis for patients with resectable pancreatic adenocarcinoma. Cancer, 85, 1250-1260.
34. Gysin,S. et al. (2005) Pharmacologic inhibition of RAF-MEK-ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. Cancer Res., 65, 4870-4880.
35. Minami,S. et al. (1997) Molecular cloning and characterization of the human p27Kip1 gene promoter. FEBS Lett., 411, 1-6.
36. Yang,W.C. et al. (2003) Targeted inactivation of p27kip1 is sufficient for large and small intestinal tumorigenesis in the mouse, which can be augmented by a western-style high-risk diet. Cancer Res. 63, 4990-4996.
37. Velcich,A. et al. (2002) Colorectal cancer in mice genetically deficent in the mucin Muc2. Science, 295, 1726-1729.